Clashing Over Rx/Dx Rights, Roche Files Suit Against DxS to Enforce Distribution Deal for KRAS, EGFR Tests
February 17, 2010
Clashing Over Rx/Dx Rights, Roche Files Suit Against DxS to Enforce Distribution Deal for KRAS, EGFR Tests
DxS denies allegations in a lawsuit filed by Roche last week that the UK-based diagnostics company is trying to renege on a distribution agreement between the two firms for KRAS and EGFR mutations tests.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Roche Charges DxS of Ditching Distribution Agreement in Favor of Parent Qiagen
February 24, 2010 / Pharmacogenomics Reporter - With New Hires to Pharma Business Development Team, Qiagen Prioritizes Rx/Dx Partnership Strategy
April 21, 2010 / Pharmacogenomics Reporter - MDx/CDx Focus: Qiagen; Dako & Amgen; Ventana & Pfizer; Foundation Medicine & Sanofi; and More
January 11, 2012 / Pharmacogenomics Reporter - Roche Gets Positive CHMP Review for Tarceva as First-line Treatment in EGFR-mutated NSCLC
July 27, 2011 / Pharmacogenomics Reporter - With Medco Around for Dx Shops Developing PGx Tests Independently, Who Needs Pharma?
April 14, 2010 / Pharmacogenomics Reporter